CAPS Rating: No stars


Player Avatar zzlangerhans (99.85) Submitted: 6/16/2011 12:46:03 AM : Outperform Start Price: $6.93 PATH.DL Score: -57.38

I caught one bottom on NuPathe last fall and missed another a couple of months ago. Now I'm betting on the stock to rise from the current 100M market cap in advance of the August 29 PDUFA for Zelrix. I'd better be right because I'm seeing a Pozen/NeurogesX/Labopharm/Biodelivery type decline after Zelrix is approved. As a reformulation of a generic, Zelrix has limited commercial potential in the crowded migraine market.

Member Avatar seanisbomb (< 20) Submitted: 7/31/2013 1:03:31 PM
Recs: 0


Featured Broker Partners